IL10 (Interleukin-10) variants and mutations
IL10 (also known as Interleukin-10) is a human protein-coding gene encoding an interleukin-10 protein. It suppresses excessive inflammatory cytokine production and restrains antigen-presenting cells and effector lymphocytes, protecting tissues from immune-mediated damage. Loss of IL-10 signaling causes severe early-onset intestinal inflammation and inflammatory bowel disease. This analysis covers 353 IL10 variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes Crohn disease, inflammatory bowel disease, and IL10-related early-onset inflammatory bowel disease. Example IL10 variants include H2R, L7F, and L7V.
Variant analysis overview
- Gene: IL10
- Protein: Interleukin-10
- UniProt accession: P22301
- Organism: Homo sapiens
- Variants analyzed: 353
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 189 unspecified-consequence records; 2 stop lost; 1 stop retained variant; 67 missense variants; 72 synonymous variants; 6 stop-gained variants; 4 splice-region variants; 9 frameshift variants; 1 in-frame deletions; 2 substitution
- Prediction scores: 334 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Crohn disease, inflammatory bowel disease, IL10-related early-onset inflammatory bowel disease, ulcerative colitis, type 1 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, Behcet disease, ulcer disease, ulcerative proctosigmoiditis, Autosomal recessive early-onset inflammatory bowel disease, cancer.
Protein structure and variant hotspots
- Protein features: 1 post-translational modification sites.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IL10 variants
Examples include H2R, L7F, L7V, L7I, C8S, C9C, L10M, L10L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- H2R (p.His2Arg), Ensembl rs1674879802, SIFT 0.18
- L7F (p.Leu7Phe), ExAC rs772299982, TOPMed rs772299982, gnomAD rs772299982, REVEL 0.36, CADD 17.90
- L7V (p.Leu7Val), ExAC rs772299982, TOPMed rs772299982, gnomAD rs772299982, REVEL 0.46, CADD 21.10
- L7I (p.Leu7Ile), gnomAD 1-206772417-G-T, REVEL 0.41, CADD 21.40
- C8S (p.Cys8Ser), TOPMed rs1320508378, gnomAD rs1320508378, REVEL 0.14, CADD 11.10
- C9C (p.Cys9Cys), gnomAD 1-206772409-G-A, CADD 9.89
- L10M (p.Leu10Met), gnomAD rs1200270622, REVEL 0.51, CADD 22.90
- L10L (p.Leu10Leu), rs762421652, gnomAD 1-206772406-C-G, AlphaMissense 0.12, MetaLR 0.03
- V11I (p.Val11Ile), ExAC rs774750635, TOPMed rs774750635, gnomAD rs774750635, REVEL 0.07, CADD 10.60
- L12L (p.Leu12Leu), rs1674878729, gnomAD 1-206772400-G-A, CADD 2.96
- L13M (p.Leu13Met), rs769236514, ClinGen CA1363854, ClinVar RCV002036385, ExAC rs769236514, REVEL 0.45, CADD 22.50, Uncertain significance, Inflammatory bowel disease
- L13L (p.Leu13Leu), rs1674878551, gnomAD 1-206772397-C-T, CADD 6.80
- T14N (p.Thr14Asn), gnomAD rs1341992326, REVEL 0.09, CADD 15.10
- G15E (p.Gly15Glu), Ensembl rs1674878202, Uncertain significance, in a family affected by Crohn disease
- G15R (p.Gly15Arg), rs145922845, ClinGen CA1363853, ClinVar RCV000767995, ClinVar RCV001257069, REVEL 0.20, CADD 10.70, Conflicting interpretations, Inflammatory bowel disease; Graft-versus-host disease, susceptibility to; Rheuma
- G15W (p.Gly15Trp), 1000Genomes rs145922845, ESP rs145922845, ExAC rs145922845, TOPMed rs145922845, Benign, in a family affected by Crohn disease
- G15G (p.Gly15Gly), gnomAD 1-206772391-C-T, CADD 0.26
- V16L (p.Val16Leu), rs1674878129, ClinGen CA344482697, ClinVar RCV002008162, Ensembl rs1674878129, REVEL 0.14, CADD 2.31, Uncertain significance, Inflammatory bowel disease
- V16V (p.Val16Val), rs780213087, gnomAD 1-206772388-C-T, CADD 2.09
- V16M (p.Val16Met), gnomAD 1-206772390-C-T, REVEL 0.08, CADD 4.67
- R17R (p.Arg17Arg), rs1338962228, gnomAD 1-206772385-C-T, CADD 2.38
- A18P (p.Ala18Pro), gnomAD 1-206772384-C-G, REVEL 0.13, CADD 6.62
- S19N (p.Ser19Asn), rs139073251, ClinGen CA1363851, ClinVar RCV000903874, 1000Genomes rs139073251, REVEL 0.23, CADD 14.60, Likely benign, Inflammatory bowel disease
- S19S (p.Ser19Ser), rs1395293404, gnomAD 1-206772379-G-A, CADD 7.21
- S19R (p.Ser19Arg), gnomAD 1-206772379-G-T, REVEL 0.34, AlphaMissense 0.26
- S19T (p.Ser19Thr), gnomAD 1-206772380-C-G, REVEL 0.23, CADD 14.20
- P20S (p.Pro20Ser), rs141219090, ClinGen CA1363850, ClinVar RCV000631402, 1000Genomes rs141219090, REVEL 0.02, CADD 6.92, Uncertain significance, Inflammatory bowel disease
- P20P (p.Pro20Pro), rs777665568, gnomAD 1-206772376-T-C, CADD 4.45
- P20T (p.Pro20Thr), gnomAD 1-206772378-G-T, REVEL 0.03, CADD 7.47
- G21D (p.Gly21Asp), rs766916310, ClinGen CA36550837, ClinVar RCV002585646, TOPMed rs766916310, REVEL 0.02, CADD 1.15, Uncertain significance, Inflammatory bowel disease
- G21G (p.Gly21Gly), gnomAD 1-206772373-G-T, CADD 2.03
- Q22R (p.Gln22Arg), gnomAD rs1674877447, REVEL 0.02, CADD 2.55
- Q22Q (p.Gln22Gln), gnomAD 1-206772370-C-T, AlphaMissense 0.07, MetaLR 0.06
- Q22* (p.Gln22Ter), gnomAD 1-206772372-G-A, CADD 32.00
- G23G (p.Gly23Gly), rs1287685346, gnomAD 1-206772367-G-C, CADD 1.14
- G23D (p.Gly23Asp), gnomAD 1-206772368-C-T, REVEL 0.06, CADD 0.07
- G23S (p.Gly23Ser), gnomAD 1-206772369-C-T, REVEL 0.03, CADD 0.01
- T24S (p.Thr24Ser), rs1674877288, ClinGen CA344482645, ClinVar RCV001217119, Ensembl rs1674877288, REVEL 0.04, AlphaMissense 0.10, Uncertain significance, Inflammatory bowel disease
- Q25* (p.Gln25Ter), NCI-TCGA Cosmic COSV6559, Variant assessed as somatic; high impact.
- Q25Q (p.Gln25Gln), gnomAD 1-206772361-C-T, CADD 4.68
- E27K (p.Glu27Lys), ExAC rs758161630, TOPMed rs758161630, gnomAD rs758161630, REVEL 0.08, CADD 19.50
- N28N (p.Asn28Asn), rs945097885, gnomAD 1-206772352-G-A, CADD 9.18
- T31I (p.Thr31Ile), rs752491913, ClinGen CA1363847, ClinVar RCV003059372, ExAC rs752491913, REVEL 0.04, CADD 10.80, Uncertain significance, Inflammatory bowel disease
- T31N (p.Thr31Asn), ExAC rs752491913, TOPMed rs752491913, gnomAD rs752491913, REVEL 0.04, CADD 7.96, Uncertain significance
- T31T (p.Thr31Thr), rs912319533, gnomAD 1-206772343-G-T, CADD 9.42
- H32N (p.His32Asn), rs376787667, ClinGen CA344482592, ClinVar RCV000631401, ClinVar RCV004791643, REVEL 0.07, CADD 15.80, Uncertain significance, not provided; not specified; Inflammatory bowel disease
- H32R (p.His32Arg), TOPMed rs1674876770, gnomAD rs1674876770, REVEL 0.10, CADD 14.50
- H32Y (p.His32Tyr), ESP rs376787667, ExAC rs376787667, TOPMed rs376787667, gnomAD rs376787667, REVEL 0.07, CADD 15.00, Uncertain significance
- H32S (p.His32Ser), gnomAD 1-206772339-AGTGG, CADD 27.20
- P34R (p.Pro34Arg), TOPMed rs1674876704, SIFT 0.01
- P34T (p.Pro34Thr), rs2102441015, ClinGen CA344482577, ClinVar RCV001359362, ClinVar RCV004728667, REVEL 0.14, CADD 15.50, Uncertain significance, Inflammatory bowel disease; not provided
- P34Q (p.Pro34Gln), gnomAD 1-206772335-G-T, REVEL 0.36, CADD 24.20
- P34S (p.Pro34Ser), gnomAD 1-206772336-G-A, REVEL 0.05, CADD 12.80
- N36K (p.Asn36Lys), ExAC rs754844545, gnomAD rs754844545, REVEL 0.12, CADD 16.70
- L37V (p.Leu37Val), TOPMed rs1186371398, gnomAD rs1186371398, REVEL 0.41, CADD 22.60
- L37L (p.Leu37Leu), rs753414785, gnomAD 1-206772325-C-G, CADD 7.24
- L37P (p.Leu37Pro), gnomAD 1-206772326-A-G, REVEL 0.81, CADD 24.60
- P38A (p.Pro38Ala), rs932830694, ClinGen CA36550762, ClinVar RCV002715848, TOPMed rs932830694, REVEL 0.52, CADD 20.30, Uncertain significance, Inflammatory bowel disease
- P38S (p.Pro38Ser), TOPMed rs932830694, REVEL 0.32, CADD 21.60, Uncertain significance
- P38P (p.Pro38Pro), rs765862851, gnomAD 1-206772322-A-G, CADD 10.40
- P38T (p.Pro38Thr), gnomAD 1-206772324-G-T, REVEL 0.34, CADD 17.00
- M40V (p.Met40Val), rs755837237, ClinGen CA1363842, ClinVar RCV003086853, ExAC rs755837237, AlphaMissense 0.22, MetaLR 0.53, Uncertain significance, Inflammatory bowel disease
- L41F (p.Leu41Phe), rs750010814, ClinGen CA1363841, ClinVar RCV001986893, ExAC rs750010814, REVEL 0.69, CADD 25.30, Uncertain significance, Inflammatory bowel disease
- R42* (p.Arg42Ter), rs1274280163, NCI-TCGA Cosmic COSV6559, gnomAD rs1274280163, AlphaMissense 0.21, MetaLR 0.42, Variant assessed as somatic; high impact.
- R42G (p.Arg42Gly), rs1274280163, NCI-TCGA Cosmic COSV6559, gnomAD rs1274280163, AlphaMissense 0.21, MetaLR 0.42, Variant assessed as somatic; moderate impact.
- R42Q (p.Arg42Gln), ExAC rs767158016, TOPMed rs767158016, gnomAD rs767158016, REVEL 0.17, CADD 16.00
- R42L (p.Arg42Leu), gnomAD 1-206772311-C-A, REVEL 0.25, CADD 16.40
- D43N (p.Asp43Asn), NCI-TCGA TCGA novel, SIFT 1.00, Variant assessed as somatic; moderate impact.
- D43D (p.Asp43Asp), gnomAD 1-206772307-A-G, CADD 6.31
- L44L (p.Leu44Leu), rs774794282, gnomAD 1-206772304-G-C, CADD 6.66
- R45* (p.Arg45Ter), 1000Genomes rs570050304, ExAC rs570050304, gnomAD rs570050304, CADD 35.00
- R45Q (p.Arg45Gln), rs550164520, ClinGen CA1363835, ClinVar RCV001042351, 1000Genomes rs550164520, REVEL 0.64, CADD 25.30, Uncertain significance, Inflammatory bowel disease
- R45P (p.Arg45Pro), gnomAD 1-206772302-C-G, REVEL 0.72, CADD 25.60
- R45R (p.Arg45Arg), rs570050304, gnomAD 1-206772303-G-T, CADD 9.06
- D46G (p.Asp46Gly), rs769965755, ClinGen CA1363834, ClinVar RCV003025916, ExAC rs769965755, REVEL 0.09, CADD 7.82, Uncertain significance, Inflammatory bowel disease
- D46V (p.Asp46Val), ExAC rs769965755, TOPMed rs769965755, gnomAD rs769965755, SIFT 0.61, Uncertain significance
- A47T (p.Ala47Thr), TOPMed rs1674875242
- A47V (p.Ala47Val), TOPMed rs1373589952, gnomAD rs1373589952, REVEL 0.50, CADD 24.70
- A47A (p.Ala47Ala), gnomAD 1-206772295-G-A, CADD 9.88
- A47D (p.Ala47Asp), gnomAD 1-206772296-G-T, REVEL 0.51, CADD 24.90
- A47S (p.Ala47Ser), gnomAD 1-206772297-C-A, REVEL 0.44, CADD 23.10
- F48L (p.Phe48Leu), rs745923816, ExAC rs745923816, TOPMed rs745923816, gnomAD rs745923816, REVEL 0.53, CADD 15.10, Variant assessed as somatic; moderate impact.
- F48F (p.Phe48Phe), rs745923816, gnomAD 1-206772292-G-A, CADD 1.72
- R50K (p.Arg50Lys), NCI-TCGA Cosmic COSV6559, SIFT 0.05, Variant assessed as somatic; moderate impact.
- K52E (p.Lys52Glu), TOPMed rs1674874871
- T53N (p.Thr53Asn), Ensembl rs1674874762, SIFT 0.17
- F54L (p.Phe54Leu), Ensembl rs1674874506, SIFT 0.00
- F54S (p.Phe54Ser), ExAC rs771131184, gnomAD rs771131184, REVEL 0.66, CADD 28.50
- F54Y (p.Phe54Tyr), ExAC rs771131184, gnomAD rs771131184, REVEL 0.18, CADD 21.00
- F54C (p.Phe54Cys), gnomAD 1-206772275-A-C, REVEL 0.69, CADD 28.60
- F55L (p.Phe55Leu), ExAC rs747900649, TOPMed rs747900649, gnomAD rs747900649
- F55S (p.Phe55Ser), TOPMed rs1674874269, SIFT 0.00
- Q56P (p.Gln56Pro), NCI-TCGA Cosmic COSV6559, Variant assessed as somatic; high impact.
- Q56Q (p.Gln56Gln), gnomAD 1-206771413-T-C, CADD 19.70
- Q56S (p.Gln56Ser), gnomAD 1-206771415-G-GAA, CADD 29.00
- Q56I (p.Gln56Ile), gnomAD 1-206771415-G-GAA, CADD 33.00
- M57I (p.Met57Ile), TOPMed rs1457100580, gnomAD rs1457100580, REVEL 0.16, CADD 5.92
- M57V (p.Met57Val), gnomAD 1-206771412-T-C, REVEL 0.15, CADD 18.10
- K58K (p.Lys58Lys), gnomAD 1-206771407-C-T, CADD 11.50
- D59N (p.Asp59Asn), NCI-TCGA Cosmic COSV1008, SIFT 0.00, Variant assessed as somatic; moderate impact.
- D59Y (p.Asp59Tyr), gnomAD 1-206771406-C-A, REVEL 0.87, CADD 28.00
- Q60H (p.Gln60His), gnomAD 1-206771401-C-G, REVEL 0.18, CADD 21.60
- Q60K (p.Gln60Lys), gnomAD 1-206771403-G-T, REVEL 0.07, CADD 20.10
- L61M (p.Leu61Met), gnomAD 1-206771400-G-T, REVEL 0.42, CADD 24.10
- L61L (p.Leu61Leu), rs953790639, gnomAD 1-206771400-G-A, CADD 9.98
- D62Y (p.Asp62Tyr), Ensembl rs868225905
- D62A (p.Asp62Ala), gnomAD 1-206771396-T-G, REVEL 0.39, CADD 21.80
- N63S (p.Asn63Ser), rs776711200, NCI-TCGA Cosmic COSV6559, ExAC rs776711200, gnomAD rs776711200, REVEL 0.15, CADD 0.56, Variant assessed as somatic; moderate impact.
- N63N (p.Asn63Asn), rs1477332544, gnomAD 1-206771392-G-A, CADD 7.27
- L64S (p.Leu64Ser), Ensembl rs756548976, REVEL 0.06, CADD 8.88
- L64W (p.Leu64Trp), Ensembl rs756548976, REVEL 0.13, CADD 19.50
- L64M (p.Leu64Met), gnomAD 1-206771391-A-T, REVEL 0.03, CADD 0.32
- L65L (p.Leu65Leu), gnomAD 1-206771386-C-T, CADD 7.83
- L66L (p.Leu66Leu), gnomAD 1-206771383-T-C, CADD 6.10
- L66del (p.Leu66del), rs1473801814, gnomAD 1-206771383-TAAC-, CADD 15.50
- K67N (p.Lys67Asn), gnomAD 1-206771380-C-A, REVEL 0.08, CADD 0.57
- E68G (p.Glu68Gly), ExAC rs747219677, TOPMed rs747219677, gnomAD rs747219677, REVEL 0.04, CADD 16.70
- E68K (p.Glu68Lys), gnomAD rs1194370056, REVEL 0.05, CADD 6.68
- S69S (p.Ser69Ser), gnomAD 1-206771374-G-A, CADD 5.21
- L70* (p.Leu70Ter), rs1558603013, ClinGen CA344482310, ClinVar RCV001947523, Ensembl rs1558603013, Uncertain significance
- L71M (p.Leu71Met), 1000Genomes rs200783164, ESP rs200783164, ExAC rs200783164, TOPMed rs200783164, REVEL 0.47, CADD 24.90, Uncertain significance, not specified
- L71L (p.Leu71Leu), rs1674835162, gnomAD 1-206771368-C-A, CADD 11.60
- E72G (p.Glu72Gly), rs545228684, ClinGen CA1363810, ClinVar RCV004143279, 1000Genomes rs545228684, REVEL 0.44, CADD 33.00, Uncertain significance, not specified
- K75E (p.Lys75Glu), gnomAD 1-206771358-T-C, REVEL 0.57, CADD 24.50
- G76G (p.Gly76Gly), rs139352858, gnomAD 1-206771057-A-G, CADD 17.60
- Y77H (p.Tyr77His), NCI-TCGA TCGA novel, Ensembl rs1674817039, Variant assessed as somatic; moderate impact.
- L78L (p.Leu78Leu), gnomAD 1-206771051-C-T, CADD 13.20
- G79G (p.Gly79Gly), gnomAD 1-206771048-A-T, CADD 9.71
- C80* (p.Cys80Ter), TOPMed rs1674816820
- C80Y (p.Cys80Tyr), NCI-TCGA Cosmic COSV6559, Ensembl rs2102439327, SIFT 0.00, Variant assessed as somatic; moderate impact.
- Q81K (p.Gln81Lys), rs2102439318, ClinGen CA344482223, ClinVar RCV002028295, Ensembl rs2102439318, AlphaMissense 0.43, MetaLR 0.39, Uncertain significance, Inflammatory bowel disease
- A82S (p.Ala82Ser), ExAC rs772231902, gnomAD rs772231902, REVEL 0.46, CADD 23.20
- A82V (p.Ala82Val), TOPMed rs1422818800, gnomAD rs1422818800, REVEL 0.49, CADD 27.90
- L83F (p.Leu83Phe), ExAC rs762750138, gnomAD rs762750138, REVEL 0.59, CADD 24.50, Uncertain significance, not specified
- L83V (p.Leu83Val), TOPMed rs1476564089
- L83L (p.Leu83Leu), gnomAD 1-206771038-A-G, CADD 12.60
- S84S (p.Ser84Ser), rs775288303, gnomAD 1-206771033-A-C, CADD 3.86
- S84A (p.Ser84Ala), rs772231902, []
- E85E (p.Glu85Glu), rs769682299, gnomAD 1-206771030-C-T, CADD 12.40
- E85R (p.Glu85Arg), gnomAD 1-206771032-CA-C, CADD 13.60
- M86I (p.Met86Ile), NCI-TCGA Cosmic COSV6559, Variant assessed as somatic; moderate impact.
- M86K (p.Met86Lys), rs2526391945, ClinGen CA344482187, ClinVar RCV003034406, Uncertain significance, Inflammatory bowel disease
- M86V (p.Met86Val), TOPMed rs1674815823, SIFT 0.05
- I87V (p.Ile87Val), TOPMed rs1674815680, SIFT 0.66
- I87I (p.Ile87Ile), gnomAD 1-206771024-G-A, CADD 13.80
- Q88H (p.Gln88His), TOPMed rs1674815409, gnomAD rs1674815409, REVEL 0.36, CADD 22.70
- Q88R (p.Gln88Arg), gnomAD 1-206771022-T-C, REVEL 0.20, CADD 22.10
- Q88E (p.Gln88Glu), gnomAD 1-206771023-G-C, REVEL 0.26, CADD 20.20
- Y90H (p.Tyr90His), gnomAD 1-206771017-A-G, REVEL 0.85, CADD 29.20
- L91V (p.Leu91Val), ExAC rs745801059, gnomAD rs745801059, REVEL 0.76, CADD 24.20
- L91L (p.Leu91Leu), rs1674815134, gnomAD 1-206771012-C-T, CADD 12.20
- L91P (p.Leu91Pro), gnomAD 1-206771013-A-G, REVEL 0.88, CADD 29.50
- E92K (p.Glu92Lys), rs780612967, ClinGen CA1363787, ClinVar RCV001228939, ExAC rs780612967, REVEL 0.34, CADD 23.90, Uncertain significance, Inflammatory bowel disease
- E92Q (p.Glu92Gln), ExAC rs780612967, gnomAD rs780612967, SIFT 0.17, Uncertain significance
- E92E (p.Glu92Glu), rs1674814817, gnomAD 1-206771009-C-T, CADD 8.31
- E93Q (p.Glu93Gln), ExAC rs770531048, SIFT 0.39
- E93D (p.Glu93Asp), gnomAD 1-206771006-C-G, REVEL 0.14, CADD 16.60
- E93K (p.Glu93Lys), gnomAD 1-206771008-C-T, REVEL 0.29, CADD 23.30
- V94D (p.Val94Asp), gnomAD 1-206771002-TCA-T, CADD 32.00
- V94V (p.Val94Val), gnomAD 1-206771003-C-T, CADD 13.40
- V94L (p.Val94Leu), gnomAD 1-206771005-C-A, REVEL 0.78, CADD 26.00
- M95I (p.Met95Ile), ExAC rs746471077, gnomAD rs746471077, REVEL 0.55, CADD 24.10
- M95T (p.Met95Thr), TOPMed rs1354773439, gnomAD rs1354773439, REVEL 0.76, CADD 26.80
- Q97K (p.Gln97Lys), rs756460032, gnomAD 1-206770995-TG-T, CADD 23.50
- Q97* (p.Gln97Ter), gnomAD 1-206770996-G-A, CADD 35.00
- A98D (p.Ala98Asp), gnomAD rs1421978042, REVEL 0.72, CADD 27.80
- A98T (p.Ala98Thr), Ensembl rs2102439246
- A98V (p.Ala98Val), gnomAD 1-206770992-G-A, REVEL 0.56, CADD 25.50
- E99D (p.Glu99Asp), gnomAD 1-206770988-C-G, REVEL 0.35, CADD 22.70
- E99E (p.Glu99Glu), rs1220388430, gnomAD 1-206770988-C-T, CADD 11.00
- N100I (p.Asn100Ile), Ensembl rs2102439235, SIFT 0.18
- N100K (p.Asn100Lys), NCI-TCGA TCGA novel, Ensembl rs2102439232, REVEL 0.08, CADD 15.10, Variant assessed as somatic; moderate impact.
- Q101* (p.Gln101Ter), ExAC rs777582308, TOPMed rs777582308, gnomAD rs777582308, CADD 36.00, Uncertain significance
- Q101K (p.Gln101Lys), rs777582308, ClinGen CA1363783, ClinVar RCV001941321, ExAC rs777582308, REVEL 0.09, CADD 13.90, Uncertain significance, Inflammatory bowel disease
- Q101R (p.Gln101Arg), ExAC rs758058722, TOPMed rs758058722, gnomAD rs758058722, REVEL 0.13, CADD 19.50
- D102A (p.Asp102Ala), NCI-TCGA TCGA novel, Ensembl rs1674813773, REVEL 0.10, CADD 16.30, Variant assessed as somatic; moderate impact.
- D102E (p.Asp102Glu), gnomAD 1-206770979-G-T, REVEL 0.07, CADD 7.09
- P103S (p.Pro103Ser), ExAC rs753179739, gnomAD rs753179739, REVEL 0.28, CADD 18.10
- P103P (p.Pro103Pro), rs987614203, gnomAD 1-206770976-T-C, CADD 7.59
- D104H (p.Asp104His), ESP rs376002450
Public IL10 analysis runs
- IL10 analysis run — IL10 (353 variants) — completed 2026-08-19